Modular Phase 1B Hypothesis-Testing, Biomarker-Driven, Talazoparib Combination Trial (TalaCom)
This study tests a new combination of targeted cancer drugs to see which doses work best and how well they fight advanced solid tumors. By combining a DNA-repair blocker called talazoparib with other cancer-fighting medications, researchers hope to stop cancer cells from growing and repairing themselves.
You might be able to join if you have an advanced solid tumor with specific gene changes, such as BRCA1/2, PALB2, or MYC mutations, confirmed by testing. However, you cannot join if you recently had major surgery, other anti-cancer treatments within two weeks, or untreated active cancer in the brain.
Participants will receive talazoparib paired with one of three other targeted therapies (palbociclib, axitinib, or crizotinib) to help control their cancer. Your health team will carefully monitor you to find the safest and most effective dose while watching for any side effects.
This study is currently recruiting participants and takes place in Houston, Texas, United States. Your care team will guide you through all the necessary visits and check-ups during the process.
- 1Tests combining talazoparib with other targeted cancer medications
- 2Aimed at patients with advanced solid tumors and specific gene changes
- 3Currently recruiting patients in Houston, Texas
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.